|Mr. Michael J. Parini J.D.||CEO, COO, Pres & Exec. Director||1.13M||N/A||1975|
|Dr. Amit Chunilal Nathwani M.D., Ph.D.||Founder, Independent Clinical & Scientific Advisor and Director||513k||N/A||1960|
|Dr. Markus Horer Ph.D.||Founder, CTO & Managing Director GmbH||N/A||N/A||1967|
|Mr. Stephen P. Diamond Jr.||Sr. VP, Gen. Counsel & Company Sec.||N/A||N/A||1972|
|Mr. Mark Baldry M.B.A.||Chief Commercial Officer||N/A||N/A||1964|
|Mr. James Bircher||Chief Technical Operations Officer||N/A||N/A||1969|
|Dr. Pamela Foulds M.D.||Chief Medical Officer||N/A||N/A||1970|
|Ms. Amy J. Spandau||Interim Head of Fin.||N/A||N/A||1976|
|Dr. Henning R. Stennicke Ph.D.||Chief Scientific Officer||N/A||N/A||1968|
|Arne Naeveke Ph.D.||VP & Head of Corp. Communications||N/A||N/A||N/A|
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease and is under Phase 1/2 clinical trial. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.
Freeline Therapeutics Holdings plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.